MedTrace Logo

A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors

NCT04947033 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2023-03-14

No results posted yet for this study

Summary

A phase I clinical study evaluating TJ210001 in the treatment of subjects with advanced solid tumors

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

TJ210001 Injection

The test drug TJ210001 will be preset with 5 escalation dose levels: 0.3mg/kg, 1mg/kg, 3mg/kg, 10mg/kg and 15mg/kg, administered once a week.

Sponsors & Collaborators

  • I-Mab Biopharma US Limited

    lead INDUSTRY

Principal Investigators

  • Jin Li · Shanghai East Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-31
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04947033 on ClinicalTrials.gov